Left to right: AbCellera head of BD Kevin Heyries, CEO Carl Hansen, COO Véronique Lecault, head of corporate development Murray McCutcheon
May 27, 2020 05:04 AM EDTUpdated 10:08 AM
Financing

Ab­Cellera rais­es $105M in first ma­jor ven­ture round as Covid-19 an­ti­body nears clin­ic

Jason Mast

Editor

Over its first decade of ex­is­tence, Ab­Cellera had many things: A new tech­nol­o­gy with sci-fi vibes, fund­ing from the Bill & Melin­da Gates Foun­da­tion, gov­ern­ment …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times